 Delcath Systems, Inc. DCTH, an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announces financial results for the quarter ended March 31, 2020. First quarter and year to date, we achieved major milestones, commented Jennifer Simpson, PhD., M.S.N., C.R.N.P., President Chief Executive Officer. 